Loading clinical trials...
Loading clinical trials...
A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients With Relapsed or Refractory Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Ohio State University
Columbus, Ohio, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
CTRC at UTHSCSA
San Antonio, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
Start Date
January 1, 2012
Primary Completion Date
July 1, 2016
Completion Date
July 1, 2016
Last Updated
December 29, 2017
49
ACTUAL participants
IMGN529
DRUG
Lead Sponsor
ImmunoGen, Inc.
NCT07277231
NCT05006716
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06859424